BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 23739841)

  • 1. Anticoagulation beyond direct thrombin and factor Xa inhibitors: indications for targeting the intrinsic pathway?
    van Montfoort ML; Meijers JC
    Thromb Haemost; 2013 Aug; 110(2):223-32. PubMed ID: 23739841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
    Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intrinsic pathway of coagulation and arterial thrombosis.
    Gailani D; Renné T
    Arterioscler Thromb Vasc Biol; 2007 Dec; 27(12):2507-13. PubMed ID: 17916770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factor XI and XII as antithrombotic targets.
    Müller F; Gailani D; Renné T
    Curr Opin Hematol; 2011 Sep; 18(5):349-55. PubMed ID: 21730835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct inhibitors of coagulation proteins - the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy?
    Laux V; Perzborn E; Heitmeier S; von Degenfeld G; Dittrich-Wengenroth E; Buchmüller A; Gerdes C; Misselwitz F
    Thromb Haemost; 2009 Nov; 102(5):892-9. PubMed ID: 19888525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New oral anticoagulants in development.
    Weitz JI
    Thromb Haemost; 2010 Jan; 103(1):62-70. PubMed ID: 20062934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel anticoagulants in clinical development: focus on factor Xa and direct thrombin inhibitors.
    Steffel J; Lüscher TF
    J Cardiovasc Med (Hagerstown); 2009 Aug; 10(8):616-23. PubMed ID: 19561526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
    Melo FR; Mourão PA
    Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New anticoagulants for atrial fibrillation.
    De Caterina R; Kristensen SD; Renda G
    J Cardiovasc Med (Hagerstown); 2009 Jun; 10(6):446-53. PubMed ID: 19365276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct Factor Xa and direct thrombin inhibitors: a clinical trial update.
    Turpie AG
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):497-508. PubMed ID: 19562646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Concepts in anticoagulant therapy - past, present, and future].
    Graf L
    Ther Umsch; 2012 Nov; 69(11):611-5. PubMed ID: 23117663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective inhibition of coagulation factors: advances in antithrombotic therapy.
    Bauer KA
    Semin Thromb Hemost; 2002 Jun; 28 Suppl 2():15-24. PubMed ID: 12073176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors IX, XI, and XII: potential therapeutic targets for anticoagulant therapy in atherothrombosis.
    Rai V; Balters MW; Agrawal DK
    Rev Cardiovasc Med; 2019 Dec; 20(4):245-253. PubMed ID: 31912715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factor XI and factor XII as targets for new anticoagulants.
    Weitz JI
    Thromb Res; 2016 May; 141 Suppl 2():S40-5. PubMed ID: 27207423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Old and new anticoagulant agents for the prevention and treatment of patients with ischemic stroke.
    Martí-Fàbregas J; Mateo J
    Cerebrovasc Dis; 2009; 27 Suppl 1():111-9. PubMed ID: 19342840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticoagulant drugs: what is new?
    Kei A; Florentin M; Elisaf M; Liberopoulos E
    Int Angiol; 2011 Aug; 30(4):299-320. PubMed ID: 21747349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meeting the unmet needs in anticoagulant therapy.
    Weitz JI
    Eur J Haematol Suppl; 2010 Jul; (72):1-28. PubMed ID: 20553560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors.
    Kaatz S; Kouides PA; Garcia DA; Spyropolous AC; Crowther M; Douketis JD; Chan AK; James A; Moll S; Ortel TL; Van Cott EM; Ansell J
    Am J Hematol; 2012 May; 87 Suppl 1():S141-5. PubMed ID: 22473649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the Working Group on Perioperative Haemostasis and the French Study Group on Thrombosis and Haemostasis.
    Sié P; Samama CM; Godier A; Rosencher N; Steib A; Llau JV; Van der Linden P; Pernod G; Lecompte T; Gouin-Thibault I; Albaladejo P; ;
    Arch Cardiovasc Dis; 2011 Dec; 104(12):669-76. PubMed ID: 22152517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.